Distribution of IgG subclasses after anti-hepatitis B virus immunization with a recombinant vaccine

M. C. Honorati, R. M. Borzì, P. Dolzani, S. Toneguzzi, A. Facchini

Research output: Contribution to journalArticlepeer-review

Abstract

To assess whether a different IgG subclass distribution was elicited in 'low' and 'high responders' after vaccination with recombinant hepatitis B virus surface antigen, we selected from 360 vaccine recipients 30 'low-responder' subjects, with anti-HBs levels of 10-160 mIU/ml, and 40 'high-responder' subjects, with anti-HBs levels greater than 10,000 mIU/ml. In both groups all IgG subclasses were elicited in the anti-HBs response and the greatest contribution was that of IgG1, followed by IgG2. IgG1 was significantly less represented after the second (58%) and third doses (61%) of vaccine in 'low responders' compared with 'high responders' (65% and 69%). The relative percentage of IgG2 was significantly higher after the second (33%) and third (30%) doses of vaccine in 'low responders' than in 'high responders' (29% and 26%). In 'low responders' the age of vaccine recipients significantly influenced the anti-HBs IgG subclass distribution: IgG2 and IgG4 production was positively correlated with age, whereas the opposite was observed for IgG1. These data support the evidence that: (1) IgG1 and IgG2 subclasses are mainly involved in the specific anti-HBs response both in 'high' and 'low responders'; (2) the relative contribution of specific IgG2 to vaccination is higher in low responders and progressively increases with age.

Original languageEnglish
Pages (from-to)202-206
Number of pages5
JournalInternational Journal of Clinical & Laboratory Research
Volume27
Issue number3
Publication statusPublished - Sep 1997

Keywords

  • Hepatitis B virus surface antigen
  • IgG subclasses
  • Recombinant vaccine

ASJC Scopus subject areas

  • Clinical Biochemistry

Fingerprint

Dive into the research topics of 'Distribution of IgG subclasses after anti-hepatitis B virus immunization with a recombinant vaccine'. Together they form a unique fingerprint.

Cite this